文献速递乳腺癌

老年激素受体阳性HER2阴性转移性乳腺癌患者CDK4/6抑制剂联合芳香化酶抑制剂疗效与安全性:FDA汇总分析

Outcomes of Older Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis.
PubMed 文献 · J Clin Oncol · 2019-09-27

该FDA汇总分析纳入三项随机对照研究共1827例绝经后激素受体阳性HER2阴性转移性乳腺癌患者,评估CDK4/6抑制剂联合芳香化酶抑制剂(AI)一线治疗在老年女性中的疗效与安全性。结果显示≥75岁患者联合治疗组中位无进展生存期31.1个月,风险比0.49,但≥75岁患者3-4级不良事件发生率88.8%,且生活质量较基线下降。

要点

  • ≥75岁患者CDK4/6抑制剂联合AI较AI单药显著改善PFS,HR 0.49。
  • ≥75岁患者3-4级不良事件发生率88.8%,高于<75岁的73.4%。
  • ≥75岁患者无论是否联合CDK4/6抑制剂,EQ-5D生活质量均较基线下降。

核心结论

  • 在老年女性激素受体阳性HER2阴性转移性乳腺癌一线治疗中,CDK4/6抑制剂联合AI的疗效与年轻患者相似。
  • ≥75岁患者毒性发生率更高、剂量调整更多,且生活质量较基线下降。

研究设计与样本

  • FDA汇总分析,纳入三项随机对照研究,共1827例绝经后激素受体阳性HER2阴性转移性乳腺癌患者,接受不同CDK4/6抑制剂联合AI一线治疗。
  • 采用Kaplan-Meier法和Cox比例风险回归模型评估年龄对无进展生存期的影响。

主要发现

  • ≥75岁患者(n=198)接受CDK4/6抑制剂联合AI,风险比0.49(95%CI 0.31-0.76),估计中位无进展生存期31.1个月(95%CI 20.2个月-未达到),AI单药组为13.7个月(95%CI 10.9-24.9个月)。
  • ≥75岁患者3-4级不良事件发生率为88.8%,<75岁患者为73.4%。
  • ≥75岁患者使用EQ-5D评估的生活质量指标下降,无论接受AI单药还是联合CDK4/6抑制剂。

关键数值与推荐

  • ≥75岁患者联合治疗组中位PFS 31.1个月(95%CI 20.2-未达到),AI单药组13.7个月(95%CI 10.9-24.9),HR 0.49(95%CI 0.31-0.76)。
  • ≥75岁患者3-4级不良事件发生率88.8%,<75岁为73.4%。

临床怎么用

  • ≥75岁激素受体阳性HER2阴性转移性乳腺癌患者可考虑CDK4/6抑制剂联合AI一线治疗,但需密切监测毒性并加强支持治疗。
  • 治疗过程中应关注剂量调整和生活质量变化,个体化权衡获益与风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Many older women will be treated with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor and an aromatase inhibitor (AI), given US Food and Drug Administration approval of three agents in this class. The current pooled analysis examines the efficacy and safety of this combination in older women. PATIENTS AND METHODS: We pooled data from three randomized controlled studies (N = 1,827) of different CDK4/6 inhibitors in combination with an AI for initial treatment of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer. The effect of age on progression-free survival was evaluated using Kaplan-Meier estimates and a Cox proportional hazards regression model. RESULTS: For patients age 75 years or older (n = 198) who were treated with a CDK4/6 inhibitor and an AI, hazard ratio was 0.49 (95% CI, 0.31 to 0.76) with an estimated median progression-free survival of 31.1 months (95% CI, 20.2 months to not reached) versus 13.7 months (95% CI, 10.9 months to 24.9 months) for those treated with an AI. Incidence of grade 3 to 4 adverse events was 88.8% in patients age 75 years and older and 73.4% in patients younger than age 75 years. Patients age 75 years or older reported a decline in quality-of-life measures using the EQ-5D regardless of treatment with AI alone or with the addition of a CDK4/6 inhibitor. CONCLUSION: There was similar efficacy with a CDK4/6 inhibitor in combination with an AI compared with AI alone for first-line treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer in older women compared with younger patients. Patients older than age 75 years experienced higher rates of toxicity, dose modifications, and a decrease from baseline in quality-of-life measures.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Howie LJ, Singh H, Bloomquist E, et al. Outcomes of Older Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis. J Clin Oncol. 2019. PMID: 31560580. doi:10.1200/JCO.18.02217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。